Surfactant protein D in Chornic Obstructive Pulmonary Disease (COPD)

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 8, Issue 1, 2014, Pages 42-47

  Moreno, Dolores ^a   Garcia, Alexis ^a   Lema, Diego ^a   De Sanctis, Juan B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Biomarkers; COPD; Exacerbations; Genetic polymorphism; Lung surfactant; SP D

Indexed keywords

SURFACTANT PROTEIN D; BIOLOGICAL MARKER;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DNA POLYMORPHISM; HEALTH STATUS; HUMAN; INFLAMMATION; LUNG ALVEOLUS MACROPHAGE; LUNG CLEARANCE; LUNG FUNCTION; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT RESPONSE; BIOLOGICAL MODEL; BLOOD; GENETIC POLYMORPHISM; GENETICS; PATENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BIOLOGICAL MARKERS; HUMANS; MODELS, BIOLOGICAL; PATENTS AS TOPIC; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 84895470395     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214808666140209142640     Document Type: Article

References (58)

1. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007; 370: 765-73.
2. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012; 379 (9823): 1341-51.
3. García A, Moreno D, Garmendia JV, De Sanctis JB. Biomarkers in asthma and COPD. Recent Patent Biomark 2013; 3(2): 137-44.
4. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD: Identification, definition and implications for guidelines. Arch Bronconeumol 2012; 48(3): 86-98.
5. Larocca NE, Moreno D, Garmendia JV, De Sanctis JB. New pharmacological treatments for patients with chronic obstructive pulmonary disease (COPD). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155(1): 43-50.
6. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 2007; 293(2): L259-71.
7. Crouch E, Wright JR. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001; 63: 521-54.
8. Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: Humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-78.
9. Jäkel A, Qaseem AS, Kishore U, Sim RB. Ligands and receptors of lung surfactant proteins SP-A and SP-D. Front Biosci 2013; 18: 1129-40.
10. Brown-Augsburger P, Hartshorn K, Chang D, Rust K, Fliszar C, Welgus HG, et al. Site-directed mutagenesis of Cys-15 and Cys-20 of pulmonary surfactant protein D. Expression of a trimeric protein with altered anti-viral properties. J Biol Chem 2003; 271:13724-30.
11. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165(7): 3934-40.
12. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005; 5(1): 58-68.
13. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front Immunol 2012; 3: 13.
14. Cheng G, Ueda T, Numao T, Kuroki Y, Nakajima H, Fukushima Y, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000; 16(5): 831-5.
15. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152(6 Pt1): 1860-6.
16. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: A pilot study. BMC Pulm Med 2007; 7: 13.
17. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. ECLIPSE Investigators. Am J Respir Crit Care Med 2012; 185(10): 1065-72.
18. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J 2004; 24(6): 964-70.
19. Moré JM, Voelker DR, Silveira LJ, Edwards MG, Chan ED, Bowler RP. Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease. BMC Pulm Med 2010; 10: 53.
20. Mutti A, Corradi M, Goldoni M, Vettori MV, Bernard A, Apostoli P. Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest 2006; 129(5): 1288-97.
21. Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011; 44(3): 316-22.
22. Shakoori TA, Sin DD, Bokhari SN, Ghafoor F, Shakoori AR. SP-D polymorphisms and the risk of COPD. Dis Markers 2012; 33(2): 91-100.
23. Ishii T, Hagiwara K, Kamio K, Ikeda S, Arai T, Mieno MN, et al. Involvement of surfactant protein D in emphysema revealed by genetic association study. Eur J Hum Genet 2012; 20(2): 230-5.
24. Lin Z, John G, Hegarty JP, Berg A, Yu W, Wang Y, et al. Genetic variants and monoallelic expression of surfactant protein-D in inflammatory bowel disease. Ann Hum Genet 2011; 75(5): 559-68.
25. Pueyo N, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Bonàs S, et al. Common genetic variants of surfactant protein-D (SP-D) are associated with type 2 diabetes. PLoS One 2013; 8(4): e60468.
26. Lee CT, Mao IC, Lin CH, Lin SH, Hsieh MC. Chronic obstructive pulmonary disease: A risk factor for type 2 diabetes: A nationwide population-based study. Eur J Clin Invest 2013; 43(11): 1113-9.
27. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, et al. Evaluation of COPD Longitudinally to identify predictive surrogate endpoints study investigators. serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34(1): 95-102.
28. Rust K, Bingle L, Mariencheck W, Persson A, Crouch EC. Characterization of the human surfactant protein D promoter: Transcriptional regulation of SP-D gene expression by glucocorticoids. Am J Respir Cell Mol Biol 1996; 14(2): 121-30.
29. Mariencheck W, Crouch E. Modulation of surfactant protein D expression by glucocorticoids in fetal rat lung. Am J Respir Cell Mol Biol 1994; 10(4): 419-29.
30. Ju CR, Liu W, Chen RC. Serum surfactant protein D: Biomarker of chronic obstructive pulmonary disease. Dis Markers 2012; 32(5): 281-7.
31. Ozyurek BA, Ulasli SS, Bozbas SS, Bayraktar N, Akcay S. Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8(1): 36.
32. Stuart LM, Henson PM, Vandivier RW. Collectins: Opsonins for apoptotic cells and regulators of inflammation. Curr Dir Autoimmun 2006; 9: 143-61.
33. Tam A, Sin DD. Pathobiologic mechanisms of chronic obstructive pulmonary disease. Med Clin North Am 2012; 96(4): 681-98.
34. Tzouvelekis A, Kostikas K, Bouros D. Autoimmunity and chronic obstructive pulmonary disease: Thinking beyond cigarette smoke. Am J Respir Crit Care Med 2012; 185(11): 1248-9.
35. Kheradmand F, Shan M, Xu C, Corry DB. Autoimmunity in chronic obstructive pulmonary disease: Clinical and experimental evidence. Expert Rev Clin Immunol 2012; 8(3): 285-92.
36. Packard TA, Li QZ, Cosgrove GP, Bowler RP, Cambier JC. COPD is associated with production of autoantibodies to a broad spectrum of self-antigens, correlative with disease phenotype. Immunol Res 2013; 55(1-3): 48-57.
37. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: Where do we stand? Mediators Inflamm 2013; 2013: 413735.
38. Hartshorn KL, White MR, Smith K, Sorensen G, Kuroki Y, Holmskov U, et al. Increasing antiviral activity of surfactant protein D trimers by introducing residues from bovine serum collectins: Dissociation of mannan-binding and antiviral activity. Scand J Immunol 2010; 72: 22-30.
39. Jäkel A, Clark H, Reid KB, Sim RB. Surface-bound myeloperoxidase is a ligand for recognition of late apoptotic neutrophils by human lung surfactant proteins A and D. Protein Cell 2010; 1(6): 563-72.
40. Jäkel A, Clark H, Reid KB, Sim RB. The human lung surfactant proteins A (SP-A) and D (SP-D) interact with apoptotic target cells by different binding mechanisms. Immunobiology 2010; 215(7): 551-8.
41. Litvack ML, Djiadeu P, Renganathan SD, Sy S, Post M, Palaniyar N. Natural IgM and innate immune collectin SP-D bind to late apoptotic cells and enhance their clearance by alveolar macrophages in vivo. Mol Immunol 2010; 48(1-3): 37-47.
42. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178(2): 139-48
43. Hess, G., Horsch, A., Zdunek, D. Surfactant proteins b and d for differential diagnosis of dyspnea. US20100261283 (2010).
44. Panettieri R.A., Beers, M.F., Haczku, A.F., Sims, M.W. Surfactant protein D is a biomarker for steroid responsiveness in asthma and chronic obstructive pulmonary disease. US20100143920 (2010).
45. Roth FD, Quintar AA, Leimgruber C, García L, Uribe Echevarría EM, Torres AI, et al. Restoration of the normal Clara cell phenotype after chronic allergic inflammation. Int J Exp Pathol 2013; 94(6): 399-411.
46. Whitsett, J., Ikegami, M. Surfactant protein D for the treatment of disorders associated with lung injury. US20110189104 (2011).
47. Clark, H., Nadesalingam, P., Reid, K.B.M., Strong, P. Recombinant surfactant protein D compositions and methods of use thereof. US20120010126 (2012).
48. Mahajan, L., Madan, T., Sarma, P.U., Kishore, U. Human lung surfactant protein, SP-D, modulates eosinophil activation and survival and enhances phagocytosis of apoptotic basinophils. US20080255043 (2008).
49. Neves MC, Neves YC, Mendes CM, Bastos MN, Camelier AA, Queiroz CF, et al. Evaluation of atopy in patients with COPD. J Bras Pneumol 2013; 39(3): 296-305.
50. Louie S, Zeki AA, Schivo M, Chan AL, Yoneda KY, Avdalovic M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: Pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 2013; 6(2): 197-219.
51. Fattahi F, ten Hacken NH, Löfdahl CG, Hylkema MN, Timens W, Postma DS, et al. Atopy is a risk factor for respiratory symptoms in COPD patients: Results from the EUROSCOP study. Respir Res 2013; 14: 10
52. Zhang, L., Zhang, W., Xu, J., Yang, S. Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis. US20120053141 (2012).
53. Grubor B, Meyerholz DK, Lazic T, DeMacedo MM, Derscheid RJ, Hostetter JM, et al. Regulation of surfactant protein and defensin mRNA expression in cultured ovine type II pneumocytes by alltrans retinoic acid and VEGF. Int J Exp Pathol 2006; 87(5): 393-403.
54. Fiala, K., Heslet, L. Trefoil factors (TFF) for the treatment of chronic pulmonary diseases. US20130274171 (2013).
55. Leung JM, Sin DD. Biomarkers in airway diseases. Can Respir J 2013; 20(3): 180-2.
56. Oga T, Chin K, Mishima M. Towards the next stage of novel biomarker discussion in COPD: Tekizai-Tekisho. Eur Respir J 2014; 43(2): 322-4.
57. Stockley RA. Large chronic obstructive pulmonary disease cohorts: Advantages and caution in biomarker discovery/validation. Am J Respir Crit Care Med 2013; 188(12): 1387-8.
58. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, et al. Lessons from ECLIPSE: A review of COPD biomarkers. Thorax 2013; doi: 10.1136/thoraxjnl-2013-204778.